Zobrazeno 1 - 10
of 157
pro vyhledávání: '"J. Camerlo"'
Autor:
Didier Blaise, Pierre Berger, Marc Giovannini, Anthony Gonçalves, Djamel Mokart, Christian Chabannon, J. Camerlo, Aude Charbonnier, Gilles Piana, Norbert Vey, Olivier Turrini, Agnès Tallet, Patrice Viens, Sabrina Grossi, Isabelle Brenot-Rossi, Gilles Houvenaeghel, Emmanuelle Fougereau
Publikováno v:
Clinical Hematology International
Clinical Hematology International, 2021, 3 (4), pp.119. ⟨10.2991/chi.k.210919.001⟩
Clinical Hematology International, Vol 3, Iss 4 (2021)
Clinical Hematology International, 2021, 3 (4), pp.119. ⟨10.2991/chi.k.210919.001⟩
Clinical Hematology International, Vol 3, Iss 4 (2021)
International audience; During the COVID-19 pandemic, it was rapidly established that cancer patients have an increased risk of developing severe forms of the 2019 coronavirus disease (COVID-19) due to a backlog of cancer diagnostics and immunosuppre
Publikováno v:
Oncologie. 13:271-276
Garantir un parcours personnalise pendant et apres le traitement des patients en prise en charge primaire pour des cancers du sein, des cancers colorectaux et des lymphomes malins non hodgkiniens. Dans cette situation de prise en charge primaire, les
Autor:
J. Camerlo, Brigitte Puig, François Eisinger, Marie-Hélène Giovannini, Valérie-Jeanne Bardou, Isabelle Ronda
Publikováno v:
International Journal of Cancer. 120:1136-1140
Guidelines are written to define what a physician should do, and networks set up to provide every patient with good practice. However, is willingness to treat according norms enough to actually implement it? Between 1997 and 2003, 4,533 women with in
Autor:
R. Bouabdallah, Patrick Ladaique, Didier Blaise, Karin Bilger, Mohamad Mohty, Norbert Vey, Christian Chabannon, D. Sainty, J. Camerlo, C. Arnoulet, Vadim Ivanov, D. Maraninchi, Catherine Faucher, V.J. Bardou
Publikováno v:
Transfusion. 44:501-508
BACKGROUND: RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type. STUDY DESIGN AND METHODS: An analysis was done of RBCT requirements and Hb recovery kinetic in the first 60 day
Autor:
F. Viret, Anthony Gonçalves, D. Maraninchi, J. Camerlo, G. Gravis, C. Tarpin, M. Vitot, Jean-Marc Schiano, Patrick Ladaique, A C Braud, A. Madroszyk, D. Coso, Patrice Viens, François Bertucci, G. Damaj
Publikováno v:
Oncologie. 6:49-53
La fatigue et l’anemie sont les symptomes les plus frequemment rapportes par les patients en cours de chimiotherapie. Les traitements curatifs sont souvent d’une efficacite retardee et insuffisante, et ont un cout non negligeable. Notre strategie
Autor:
C Chabannon, Dominique Genre, A. Goncalvez, D Maraninchi, J. Camerlo, G Gravis, Patrice Viens, Christel Protière, V Moutardier, V-J Bardou, G Houvenaeghel, François Bertucci, A C Braud
Publikováno v:
Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩
Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩
International audience; The aim of this study was to evaluate and to compare in terms of toxicity the modulations of dose intensity of cyclophosphamide and doxorubicin in adjuvant chemotherapy for high-risk breast cancer. Four cycles of sequential hi
Autor:
MP Mathoulin Portier, Valérie-Jeanne Bardou, Patrice Viens, Dominique Maraninchi, G Gravis, G Houvenaeghel, A C Braud, J. Jacquemier, M Begue, J. Camerlo, François Bertucci
Publikováno v:
Bone Marrow Transplantation. 29:753-757
The importance of dose intensity has been strongly emphasized in high-risk breast cancer. Overexpression of erb B2 is clearly correlated with an overall poor prognosis which could be limited in patients receiving intensive chemotherapy with alkylatin
Autor:
Anne-Marie Stoppa, J. A. Gastaut, R. Bouabdallah, D. Di Stefano, J. Camerlo, Jacques Pasquier, Valérie-Jeanne Bardou, Isabelle Brenot-Rossi, Richard Sauvan
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 28:1482-1488
Evaluation of the response to therapy is important for optimal selection of treatment strategy in patients with Hodgkin's disease (HD). Refractory disease requires intensive high-dose chemotherapy, whereas unnecessary treatment should be avoided in p
Publikováno v:
Leukemia & Lymphoma. 41:425-428
We report here a 75-year-old man from South France who developed Kaposi's Sarcoma (KS) 5 months after diagnosis of Philadelphia-chromosome positive chronic myelogenous leukemia (CML). He was found positive for HHV-8 by PCR, negative for both HIV 1 an
Autor:
Patrice Viens, Christel Protière, Gwenaelle Gravis, Dominique Genre, JP Moatti, M. Resbeut, D. Cowen, D Maraninchi, C. Alzieu, François Bertucci, J. Camerlo
Publikováno v:
Annals of Oncology. 11:39-46
Summary Background: Shared decision-making is increasingly advocated as an ideal model. However, very few studies have tested the feasibility of giving patients the opportunity to participate in the choice of treatment. Patients and methods: Women, w